Quality of Care

As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.

In AMCP's latest comments to the FDA, we emphasize the need for standardized public reporting of confirmatory trial progress, ensuring payers and health care providers have the necessary data to make informed coverage decisions. By supporting proactive communication and rigorous confirmatory trials, AMCP aims to balance early access to innovative treatments with patient safety and long-term therapeutic value.

Download the AMCP Engagement Framework at AMCP.org for Payers and Patient Organizations to find various resources, tools, examples, and instructions to guide payers and patient organizations in opening lines of communication to assist with incorporating the patient’s voice in decision-making processes.

The Health Equity Action Brief on Geographic Inequality highlights a concerning trend of widening geographic inequality over the past four decades and what managed care can do to address these potential policy biases.

AMCP's most recent Partnership Forum drew participants from a range of backgrounds and perspectives to discuss the value of collaboration between health plans/payers and patient advocacy organizations in managed care pharmacy decision-making. Senior VP of Professional and Government Affairs Jennifer Mathieu shares key insights and takeaways from the event.